Maryland’s Groundbreaking Law on Medicare Prescription Drug Savings

Maryland legislators are preparing to consider a groundbreaking law designed to extend Medicare's prescription drug savings to every resident in the state.

This proposed legislation is part of a larger movement gaining momentum across several states to make healthcare more affordable. The nonprofit organization Maryland Health Care for All! spearheaded this initiative, aiming to enable the state's prescription drug oversight board to enforce spending limits on medications reimburseable under Medicare’s Maximum Fair Prices. These prices are determined by the Inflation Reduction Act of 2022, which allows for negotiated rates on select brand-name drugs. If successful, Maryland's law could become a model for similar efforts nationwide.

For insurance professionals, the implications of this potential law are significant. By setting spending caps on prescriptions, insurance carriers and brokers might see shifts in policy pricing and coverage options. Underwriters would need to recalibrate risk assessments, particularly for policies covering drug costs, while claims professionals might witness changes in the volume and type of claims processed. This legislation underscores the growing importance of regulatory compliance and proactive policy management in an evolving healthcare landscape.

Key Considerations for Insurance Professionals

• Understand potential shifts in policy pricing and coverage as drug costs are capped.
• Evaluate the need for recalibrating risk assessments with underwritten policies.
• Monitor regulatory compliance closely to anticipate further legislative changes.
• Prepare for possible changes in claims processing related to prescription costs.